# Ascendis Pharma

Source: https://onco.cc/companies/ascendis-pharma/  
OnCo record `ascendis-pharma` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A Danish company with a long-acting growth hormone medicine approved in Europe, which also runs cancer trials of a long-acting form of the immune signal interleukin-2.

## Summary

Ascendis Pharma's oncology arm, Ascendis Pharma Oncology Division A/S, is the lead sponsor of two phase 1/2 studies on ClinicalTrials.gov. IL Believe (NCT05081609, started January 2022, active and no longer recruiting) tests TransCon IL-2 β/γ alone or with pembrolizumab, the TransCon TLR7/8 agonist, chemotherapy or trastuzumab-based treatment in advanced solid tumours, with cohorts listed for platinum-resistant ovarian cancer, melanoma after anti-PD-1 treatment, cervical cancer, non-small-cell and small-cell lung cancer and HER2-positive breast cancer. A study of the TransCon TLR7/8 agonist with or without pembrolizumab in advanced solid tumours (NCT04799054, started March 2021) is terminated. Outside cancer, the European Medicines Agency authorised its growth hormone medicine lonapegsomatropin (Skytrofa) for children and adolescents with growth hormone deficiency on 11 January 2022; the marketing authorisation holder, Ascendis Pharma Endocrinology Division A/S, is at Hellerup, Denmark.

## Fields

- Kind: Company
- Last checked: 2026-11-19
- Also known as: Ascendis Pharma A/S; Ascendis Pharma Oncology Division A/S; Ascendis Pharma Endocrinology Division A/S
- HQ: Hellerup
- Type: biotech
- Website: https://ascendispharma.com/

## Notes

- Headquarters given as Hellerup from the company's contact page (global headquarters, Tuborg Boulevard 12, 2900 Hellerup), the same address the EMA gives for the marketing authorisation holder of Skytrofa.
- NCT04799054 (TransCon TLR7/8 agonist, terminated) is not yet an OnCo trial record, so only NCT05081609 is linked.
- A third cancer study, NCT05980598 in head and neck cancer (terminated), is registered with Ascendis Pharma A/S as lead sponsor and is not an OnCo trial record either.
- No drug records exist yet for TransCon IL-2 β/γ or the TransCon TLR7/8 agonist.

## Sources

- Official website: https://ascendispharma.com/
- Ascendis Pharma: contact and headquarters address: https://ascendispharma.com/contact-us/
- ClinicalTrials.gov NCT05081609 (IL Believe): https://clinicaltrials.gov/study/NCT05081609
- ClinicalTrials.gov NCT04799054 (TransCon TLR7/8 agonist): https://clinicaltrials.gov/study/NCT04799054
- EMA: Skytrofa (lonapegsomatropin) EPAR: https://www.ema.europa.eu/en/medicines/human/EPAR/skytrofa

## Connected records

- cancers: [Cervical cancer](https://onco.cc/cancers/cervical/), [Melanoma](https://onco.cc/cancers/melanoma/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [Cytokines & engineered cytokines](https://onco.cc/technologies/cytokine-therapy/)
- trials: [A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other](https://onco.cc/trials/nct05081609/)

---
JSON: https://onco.cc/api/v1/entities/ascendis-pharma.json